Market Currents
Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY...
-
Thursday, December 8, 2011, 3:59 PM ETNektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY +35.4%) peginesatide treatment of anemia in dialysis patients. Nektar has an exclusive agreement under which it will provide Affymax with its proprietary technology for use in the drug's manufacture in exchange for manufacturing revenue, milestone and other payments.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
